Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients

[1]  J. Bergeron,et al.  Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan‐Canadian epidemiological study , 2014, British journal of haematology.

[2]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2014, Leukemia.

[3]  W. Wiktor-Jedrzejczak,et al.  Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia , 2014, Cancer.

[4]  K. Anderson,et al.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. , 2014, Blood.

[5]  D. Gibbons,et al.  Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy , 2014, Proceedings of the National Academy of Sciences.

[6]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[7]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[8]  G. Oliveira,et al.  Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation , 2014, Immunological reviews.

[9]  Sadik H. Kassim,et al.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.

[10]  K. Coombes,et al.  Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells , 2013, PloS one.

[11]  H. Goldschmidt,et al.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[12]  B. B. Weitner,et al.  Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. , 2013, Leukemia research.

[13]  Martin C. Müller,et al.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. , 2013, Blood.

[14]  G. Hoser,et al.  Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice , 2013, Leukemia.

[15]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[16]  B. Pégourié,et al.  Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. , 2013, Blood.

[17]  N. Munshi,et al.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. , 2013, Blood.

[18]  R. Larson,et al.  A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide , 2012, Journal of Hematology & Oncology.

[19]  M. Voso,et al.  Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS) , 2012 .

[20]  David A. Williams,et al.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.

[21]  J. Rogers,et al.  Differentiation syndrome in patients with acute promyelocytic leukemia , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[22]  Ash A. Alizadeh,et al.  Treatment advances have not improved the early death rate in acute promyelocytic leukemia , 2012, Haematologica.

[23]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[24]  Seung-Mo Hong,et al.  Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer , 2011, Clinical Cancer Research.

[25]  B. Barlogie,et al.  The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma , 2011, International journal of hematology.

[26]  John Crowley,et al.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.

[27]  G. Morgan,et al.  A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment , 2011, Clinical Cancer Research.

[28]  M. Schymura,et al.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. , 2011, Blood.

[29]  M. Höglund,et al.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry , 2011, Leukemia.

[30]  A. Ganser,et al.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. , 2011, Human gene therapy.

[31]  J. Mackey,et al.  Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.

[32]  E. Estey,et al.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  P. L. Bergsagel,et al.  Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) , 2010, Leukemia.

[34]  F. Roudot-thoraval,et al.  CD4+CD25+ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation , 2010, Science Translational Medicine.

[35]  T. Skorski,et al.  Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.

[36]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[37]  D. Shen,et al.  Identification of transgelin‐2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis , 2010, Cancer science.

[38]  R. Arceci.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome , 2010 .

[39]  D. Cella,et al.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.

[40]  A. Ganser,et al.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.

[41]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[42]  R. Arceci.  Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience , 2009 .

[43]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Cazzola,et al.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[46]  Jin Man Kim,et al.  Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. , 2008, Cancer genetics and cytogenetics.

[47]  T. Holyoake,et al.  Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors , 2008, Leukemia.

[48]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[49]  J. Wagner,et al.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.

[50]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[51]  H. Dombret,et al.  Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[53]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[54]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[55]  B. Neel,et al.  Phosphatidylinositol 3-Kinase p85α Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences , 2005, Molecular and Cellular Biology.

[56]  S. Marley,et al.  Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. , 2005, Clinical science.

[57]  S. Payne,et al.  Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.

[58]  R. Salgia,et al.  Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. , 2005, Blood.

[59]  T. Barbui,et al.  Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group. , 2004 .

[60]  M. Guillier,et al.  Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. , 2004, Biochemical and biophysical research communications.

[61]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[62]  A. Dalgleish,et al.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  D. Klatzmann,et al.  Efficient transduction and selection of human T‐lymphocytes with bicistronic Thy1/HSV1‐TK retroviral vector produced by a human packaging cell line , 2004, The journal of gene medicine.

[64]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  E. Sausville,et al.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.

[66]  T. Kuzel,et al.  Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. , 2003, Experimental hematology.

[67]  P. Rebulla,et al.  Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies , 2003, Transfusion.

[68]  N. Kröger,et al.  Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias , 2003, Leukemia.

[69]  T. Skorski,et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571 , 2002, Oncogene.

[70]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[71]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[72]  A. Subramanian,et al.  Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. , 2000, The Journal of biological chemistry.

[73]  J. Miguel,et al.  Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia , 1998 .

[74]  J. Miguel,et al.  Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1998, Blood.

[75]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[76]  Marietta Y. W. T. Lee,et al.  Identification of DNA replication and cell cycle proteins that interact with PCNA. , 1997, Nucleic acids research.

[77]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[78]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[79]  P. Lansdorp,et al.  Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. , 1997, Blood.

[80]  V. Broudy,et al.  Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. , 1995, The Journal of clinical investigation.